Myfortic

Myfortic is a brand name of mycophenolic acid, approved by the FDA in the following formulation(s):

MYFORTIC (mycophenolic acid - tablet, delayed release; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: February 27, 2004
  
  Strength(s): 180MG, 360MG ^[RLD]

Has a generic version of Myfortic been approved?

No. There is currently no therapeutically equivalent version of Myfortic available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Myfortic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Enteric-coated pharmaceutical compositions of mycophenolate
  Patent 6,025,391
  Issued: February 15, 2000
  Inventor(s): Haeberlin; Barbara & Mak; Ching-Pong & Meinzer; Armin & Vonderscher; Jacky
  Assignee(s): Novartis AG
  Disclosed are pharmaceutical compositions which have been modified to release pharmaceutically acceptable mycophenolate salts in the upper part of the intestinal tract and methods of treatment using the pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • April 10, 2017
    
    ✓ 
    Patent use: PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
    ✓ 
    Drug product
  
  



• 
  Entric-coated pharmaceutical compositions
  Patent 6,172,107
  Issued: January 9, 2001
  Inventor(s): Haeberlin; Barbara & Mak; Ching-Pong & Meinzer; Armin & Vonderscher; Jacky
  Assignee(s): Novartis AG
  This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.
  
  Patent expiration dates:
  
  
  • April 10, 2017
    
    ✓ 
    Patent use: PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
    ✓ 
    Drug product
  
  



• 
  Enteric coated pharmaceutical compositions
  Patent 6,306,900
  Issued: October 23, 2001
  Inventor(s): Haeberlin; Barbara & Mak; Ching-Pong & Meinzer; Armin & Vonderscher; Jacky
  Assignee(s): Novartis AG
  This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.
  
  Patent expiration dates:
  
  
  • April 10, 2017
    
    ✓ 
    Drug product
  
  

See also...

• Myfortic Consumer Information (Drugs.com)
• Myfortic Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Myfortic Consumer Information (Cerner Multum)
• Myfortic Advanced Consumer Information (Micromedex)
• Mycophenolic Acid Delayed-Release Tablets Consumer Information (Wolters Kluwer)
• Mycophenolic acid Consumer Information (Cerner Multum)
• Mycophenolate sodium Advanced Consumer Information (Micromedex)